Chemistry:Lanifibranor
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H15ClN2O4S2 |
| Molar mass | 434.91 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously.[1][2][3] As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in both steatohepatitis and fibrosis.[4]
References
- ↑ Derrett-Smith, Emma; Clark, Kristina E. N.; Shiwen, Xu; Abraham, David J.; Hoyles, Rachel K.; Lacombe, Olivier; Broqua, Pierre; Junien, Jean Louis et al. (6 September 2021). "The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis". Arthritis Research & Therapy 23 (1): 234. doi:10.1186/s13075-021-02592-x. ISSN 1478-6362. PMID 34488870.
- ↑ Boyer-Diaz, Zoe; Aristu-Zabalza, Peio; Andrés-Rozas, María; Robert, Claude; Ortega-Ribera, Martí; Fernández-Iglesias, Anabel; Broqua, Pierre; Junien, Jean-Louis et al. (May 2021). "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease". Journal of Hepatology 74 (5): 1188–1199. doi:10.1016/j.jhep.2020.11.045. PMID 33278455. https://www.journal-of-hepatology.eu/article/S0168-8278(20)33832-0/fulltext.
- ↑ Francque, Sven M.; Bedossa, Pierre; Ratziu, Vlad; Anstee, Quentin M.; Bugianesi, Elisabetta; Sanyal, Arun J.; Loomba, Rohit; Harrison, Stephen A. et al. (21 October 2021). "A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH" (in en). New England Journal of Medicine 385 (17): 1547–1558. doi:10.1056/NEJMoa2036205. ISSN 0028-4793. PMID 34670042.
- ↑ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041. PMID 37059159. https://www.cghjournal.org/article/S1542-3565(23)00265-3/fulltext#secsectitle0100.
 |  |
